Tag: diabetes drugs
-
Atypical Cases Of Diabetic Ketoacidosis (DKA) Associated With Use Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Invokana, Farxiga, And Jardiance
New Drug Safety Announcement By European Medicines Agency (EMA) Intended To Help Minimize Risk Of DKA Side Effect With This Class Of New Diabetes Drugs (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE:…
-
FDA Adds Ketoacidosis Warnings To Diabetes Drugs Invokana, Farxiga, And Jardiance As Well As Other SGLT2 Inhibitors
This Follows October 2015 Safety Alert By Health Canada Concerning Increased Risks Of Kidney Problems (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link Between DKA & Popular Diabetes…
-
New FDA Warning That Januvia, Onglyza, Tradjenta, And Nesina Are Associated With “joint pain that can be severe and disabling”
Label Changes About Side Effects For These Type 2 Diabetes Medicines In The Drug Class Called Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Posted by Tom Lamb at DrugInjuryWatch.com) In August 2015 the FDA announced…
-
In The Shadow Of Recent Announcement About Diabetes Drug Jardiance Medical Study Results There Lingers Safety Concerns For SGLT-2 Inhibitors
As With Invokana and Farxiga, Jardiance Is Subject Of Several Drug Regulatory Agency Investigations About Ketoacidosis And Other Side Effects (Posted by Tom Lamb at DrugInjuryWatch.com) ________________________________________________________________________________ UPDATE: “Health Canada Warns About Link…
-
Invokana / Farxiga / Jardiance: New Medical Study Finds A History Of Diabetic Ketoacidosis Events Is Associated With Increased Risk of Death
This Ketoacidosis Side Effect For These New Diabetes Medicines Was The Subject Of A May 2015 FDA Drug Safety Warning Which Was, Perhaps, Not Strong Enough About Dangers (Posted by Tom Lamb at…
-
Diabetes Drugs Kombiglyze And Onglyza: Heart Failure Side Effect Seems To Be Valid, And FDA Notes There Is A Possible Increased Risk Of All-Cause Mortality
As Analysis Did Not Reveal Causes Of The Increase In Death Incidents, FDA Asks Its Advisory Committee To Discuss This Safety Issue At April 2015 Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "AstraZeneca, Takeda Diabetes Drugs…
-
Diabetes Drugs Bydureon And Victoza: Thyroid Cancer Label Change In March 2015 Comes Without Much Notice
FDA Letters To AstraZeneca And Novo Nordisk Approve Addition Of Information About Increased Risk For Medullary Thyroid Carcinoma (MTC) (Posted by Tom Lamb at DrugInjuryWatch.com) The diabetes drugs Bydureon (exenatide extended-release) for injectable suspension and Victoza (liraglutide…
-
Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting
These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com)At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, results of the…
-
Byetta / Januvia / Victoza: Update On Possible Association Between These Newer Diabetes Drugs And Pancreatic Cancer As A Side Effect
Drug Safety Regulatory Developments And The Ongoing Academic Discussions About Provocative 2013 Medical Journal Article By Peter Butler At UCLA (Posted by Tom Lamb at DrugInjuryWatch.com)We last wrote about the possible association between pancreatic…